Turing again vows to cut drug's cost as compounder starts manufacturing a version

Turing Pharmaceuticals, which came under scrutiny for jacking up the price of an HIV drug from $13.50 per pill to $750 per pill, a 5,000% jump, is still promising to lower the cost of Daraprim. The company is now saying it will reduce the price by the end of the year and lay out measures to make the drug more affordable to patients, but did not say by how much. The move comes after compounding pharmacy Imprimis ($IMMY) said last month that it would offer a compounded drug that includes Daraprim's active ingredient, pyrimethamine, in capsules for $99 for a 100-count bottle. More from FiercePharma

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.